Trial Profile

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of HMI-103 Administered Intravenously in Adult Participants With Classical PKU Due to PAH Deficiency

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 12 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HMI-103 (Primary)
Indications Phenylketonuria
Focus Adverse reactions; Therapeutic Use
Acronyms pheEDIT
Sponsors Homology Medicines

Most Recent Events

05 Oct 2023 Status changed from active, no longer recruiting to discontinued.
25 Aug 2023 Status changed from recruiting to active, no longer recruiting.
14 Aug 2023 According to Homology Medicines media release, the company announced approval from the independent Data Monitoring Committee to escalate to the next dose cohort in the trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com